Role of bleomycin injection in vascular lesions around the eye

Evaluation of intralesional bleomycin in periocular and adnexal vascular lesions

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026862

Enrollment

Registered

2020-07-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H578- Other specified disorders of eye and adnexa

Interventions

Intervention1: Bleomycin: Intralesional Injection of Bleomycin will be given at a concentration of 1 IU per ml saline with 2% lignocaine at a ratio of 4:1. Total dose of bleomycin injecting would be 2

Eligibility

Inclusion criteria

Inclusion criteria: Patients above 1 year of age Periocular low flow venous malformation Periocular lymphangioma Periocular cavernous hemangioma

Exclusion criteria

Exclusion criteria: High flow vascular lesions Patients who are not willing to give consent Patients not willing for follow up Patients with impaired lung function Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Decrease in the size of the lesion or complete resolutionTimepoint: Evaluation done on post injection day 1, one week, one month and 3 months	—

Secondary

Measure	Time frame
Improvement in ptosis Cosmetic improvementTimepoint: Evaluation done on post injection day 1, one week, one month and 3 months	—

Countries

India

Contacts

Public ContactProf M S Bajaj

Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS Delhi

msbajaj32@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026